SAN DIEGO & BOSTON--(BUSINESS WIRE)--Sep 11, 2012--Illumina, Inc. (NASDAQ:ILMN) and Partners HealthCare today announced a strategic alliance to offer medical geneticists and pathologists infrastructure and networking tools to support the interpretation and reporting process for genetic sequencing data. The tools will integrate the functionality of Illumina’s MiSeq® sequencing system and Partners GeneInsight Suite ®, an IT platform that streamlines the analysis, interpretation, and reporting of complex genetic test results. The GeneInsight Suite is registered with the FDA as a Class I exempt medical device.
Through the alliance, Illumina and Partners HealthCare are leveraging their respective areas of expertise to jointly enable a comprehensive sequencing and clinically relevant reporting solution for the Illumina family of next-generation based content sets. The new tools will link to Illumina’s BaseSpace cloud computing platform and the MyGenome app for iPad®, as well as to a clinical lab’s local laboratory information system (LIS). The solution creates a seamless workflow, starting on the MiSeq and delivering results directly into the GeneInsight tool, allowing laboratory personnel to interpret data accurately and with confidence.
“Illumina and Partners HealthCare share a vision of better patient care through genomics,” said Matt Posard, Senior Vice President and General Manager of Illumina’s Translational and Consumer Genomics business. “This alliance highlights our commitment to a collaborative model that will establish the new standard in NGS clinical-based applications and enable a truly integrated, high-quality solution.” Illumina and Partners HealthCare will initially release the combined MiSeq-GeneInsight solution to a limited number of pilot customers in the clinical testing space. These pilot sites will include a select group of reference laboratories within leading academic institutions, molecular and genetic pathology laboratories looking to bring next-generation-based genetic testing in-house, and commercial reference laboratories. Additionally, Illumina will use the GeneInsight Lab® application in its CLIA-certified sequencing laboratory to support clinical interpretation and reporting.
GeneInsight software has supported the interpretation and reporting workflow for more than 24,000 complex genetic tests across multiple diagnostic reference laboratories, including Partners HealthCare Laboratory for Molecular Medicine, where the software has supported complex genetic tests since 2005.
“We expect the collaboration between our organizations to yield significant benefits to our patients, and to patients worldwide,” said Anne Klibanski, M.D., Chief Academic Officer, Partners HealthCare. “We’re excited about this extraordinary opportunity to work together to improve patient care and equally pleased that Illumina is committed to developing solutions that continue to advance our understanding of human genetics and disease.” Today, Illumina also announced the launch of TruSight™ content sets for targeted sequencing, designed for use in next-generation sequencing. The combination of the content sets and new interpretation and reporting tools is a major step forward in realizing the benefits of next generation sequencing. Illumina remains on track to submit the MiSeq system to the U.S. Food and Drug Administration (FDA) for 510(k) clearance before year end.
About Illumina Illumina ( www.illumina.com ) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.
About Partners HealthCare Partners HealthCare is an integrated health system founded by Brigham and Women’s Hospital and Massachusetts General Hospital. In addition to its two academic medical centers, the Partners system includes community and specialty hospitals, community health centers, a physician network, home health and long-term care services, and other health-related entities. Partners is one of the nation’s leading biomedical research organizations and a principal teaching affiliate of Harvard Medical School. Partners HealthCare is a non-profit organization. Further information can be found by visiting www.partners.org.
Forward-Looking Statements This release contains forward looking statements that involve risks and uncertainties. Examples of forward-looking statements include, but are not limited to, statements we make regarding the expected timing for submission of the MiSeq system to the U.S. Food and Drug Administration for 510(k) clearance. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50403491&lang=enCONTACT: Illumina, Inc.
Investors: Scott Dawson, 858-882-6665 email@example.com or Media: Jennifer Temple, 858-882-6822 firstname.lastname@example.org or Partners HealthCare Media: Rich Copp, 617-278-1031 Rcopp@partners.org KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA MASSACHUSETTS INDUSTRY KEYWORD: TECHNOLOGY DATA MANAGEMENT SOFTWARE HEALTH GENETICS HOSPITALS MEDICAL DEVICES RESEARCH FDA SCIENCE SOURCE: Illumina, Inc. Copyright Business Wire 2012 PUB: 09/11/2012 06:30 AM/DISC: 09/11/2012 06:30 AM http://www.businesswire.com/news/home/20120911005574/